JP2017537899A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537899A5
JP2017537899A5 JP2017526088A JP2017526088A JP2017537899A5 JP 2017537899 A5 JP2017537899 A5 JP 2017537899A5 JP 2017526088 A JP2017526088 A JP 2017526088A JP 2017526088 A JP2017526088 A JP 2017526088A JP 2017537899 A5 JP2017537899 A5 JP 2017537899A5
Authority
JP
Japan
Prior art keywords
compound
therapeutic agent
dissolution
formula
elution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537899A (ja
JP6829684B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061194 external-priority patent/WO2016081523A1/en
Publication of JP2017537899A publication Critical patent/JP2017537899A/ja
Publication of JP2017537899A5 publication Critical patent/JP2017537899A5/ja
Application granted granted Critical
Publication of JP6829684B2 publication Critical patent/JP6829684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526088A 2014-11-17 2015-11-17 癌を処置する方法 Active JP6829684B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US62/080,985 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US62/166,572 2015-05-26
US201562251903P 2015-11-06 2015-11-06
US62/251,903 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021008382A Division JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法

Publications (3)

Publication Number Publication Date
JP2017537899A JP2017537899A (ja) 2017-12-21
JP2017537899A5 true JP2017537899A5 (enExample) 2018-12-27
JP6829684B2 JP6829684B2 (ja) 2021-02-10

Family

ID=56014476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017526088A Active JP6829684B2 (ja) 2014-11-17 2015-11-17 癌を処置する方法
JP2021008382A Pending JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法
JP2023027585A Active JP7485810B2 (ja) 2014-11-17 2023-02-24 癌を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021008382A Pending JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法
JP2023027585A Active JP7485810B2 (ja) 2014-11-17 2023-02-24 癌を処置する方法

Country Status (20)

Country Link
US (3) US10786511B2 (enExample)
EP (2) EP3220916B1 (enExample)
JP (3) JP6829684B2 (enExample)
KR (3) KR20240035908A (enExample)
CN (2) CN116650500A (enExample)
AU (3) AU2015350108B2 (enExample)
BR (1) BR112017010166A2 (enExample)
DK (1) DK3220916T3 (enExample)
EA (1) EA201791095A1 (enExample)
ES (1) ES2947819T3 (enExample)
FI (1) FI3220916T3 (enExample)
HU (1) HUE062159T2 (enExample)
IL (4) IL296080B2 (enExample)
LT (1) LT3220916T (enExample)
MX (2) MX383484B (enExample)
PL (1) PL3220916T3 (enExample)
PT (1) PT3220916T (enExample)
SG (1) SG11201703806XA (enExample)
SI (1) SI3220916T1 (enExample)
WO (1) WO2016081523A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
RU2018145311A (ru) 2012-10-15 2019-02-18 Эпизайм, Инк. Способы лечения рака
AU2014360078A1 (en) 2013-12-06 2016-06-09 Epizyme, Inc. Combination therapy for treating cancer
PT3157527T (pt) 2014-06-17 2023-06-30 Eisai R&D Man Co Ltd Inibidores de ezh2 para tratamento de linfoma
SG11201703806XA (en) * 2014-11-17 2017-06-29 Epizyme Inc Method for treating cancer
EA201792304A1 (ru) 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
AU2017211331A1 (en) 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
EP4077314A1 (en) * 2019-12-20 2022-10-26 Epizyme, Inc. Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
US20250146080A1 (en) * 2022-02-17 2025-05-08 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
KR20250004821A (ko) 2022-04-27 2025-01-08 다이이찌 산쿄 가부시키가이샤 항체-약물 접합체와 ezh1 및/또는 ezh2 억제제의 조합

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012097222A1 (en) * 2011-01-14 2012-07-19 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AU2013232229B2 (en) * 2012-03-12 2017-11-23 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
SG10201608579UA (en) * 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
LT2836491T (lt) 2012-04-13 2017-03-27 Epizyme, Inc. Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma
JP6461802B2 (ja) 2012-10-15 2019-01-30 エピザイム，インコーポレイティド 置換ベンゼン化合物
RU2018145311A (ru) 2012-10-15 2019-02-18 Эпизайм, Инк. Способы лечения рака
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
AU2014254392B2 (en) 2013-03-15 2018-05-24 Epizyme, Inc. Substituted benzene compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
HUE063984T2 (hu) * 2013-10-16 2024-02-28 Epizyme Inc Hidroklorid só forma az EZH2 gátlásához
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
AU2014360078A1 (en) 2013-12-06 2016-06-09 Epizyme, Inc. Combination therapy for treating cancer
PT3157527T (pt) * 2014-06-17 2023-06-30 Eisai R&D Man Co Ltd Inibidores de ezh2 para tratamento de linfoma
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
SG10201903356XA (en) 2014-10-16 2019-05-30 Epizyme Inc Method for treating cancer
SG11201703806XA (en) 2014-11-17 2017-06-29 Epizyme Inc Method for treating cancer
JP6890097B2 (ja) * 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
US11147819B2 (en) * 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer

Similar Documents

Publication Publication Date Title
JP2017537899A5 (enExample)
ES2957912T3 (es) Composiciones farmacéuticas que comprenden nilotinib
KR102338802B1 (ko) 암을 치료하기 위한 방법
JP2023036772A (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
US11065240B2 (en) Drug combinations to treat multiple myeloma
ES2811110T3 (es) Composición farmacéutica capaz de la incorporación de Lenalidomida en diversas modificaciones cristalinas
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
KR102490547B1 (ko) 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
JP2024009815A (ja) アキシチニブを含有する医薬組成物
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
JP2013536243A5 (enExample)
RU2712187C2 (ru) Фармацевтические композиции и их применение
ES2792574T3 (es) Formulación de Ceritinib
JP2015534985A5 (enExample)
KR20200121302A (ko) 간세포성 암종의 치료를 위한 조합 요법
JP7370126B2 (ja) エルロチニブを有効成分とする医薬錠剤
WO2011081118A1 (ja) 経口投与用医薬組成物
JP2020075924A (ja) エルロチニブを有効成分とする医薬錠剤
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
JP2020090456A (ja) エルロチニブを有効成分とする医薬錠剤
JP2018020968A (ja) ゲフィチニブを有効成分とする医薬組成物
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
EA048689B1 (ru) Твердый фармацевтический состав для лечения рака
TW201726124A (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物